168 related articles for article (PubMed ID: 9799756)
21. Changes in biochemical markers and bone mass after withdrawal of ibandronate treatment: prediction of bone mass changes during treatment.
Ravn P; Christensen JO; Baumann M; Clemmesen B
Bone; 1998 May; 22(5):559-64. PubMed ID: 9600792
[TBL] [Abstract][Full Text] [Related]
22. The efficacy of 48-week oral ibandronate treatment in postmenopausal osteoporosis when taken 30 versus 60 minutes before breakfast.
Tankó LB; McClung MR; Schimmer RC; Mahoney P; Christiansen C
Bone; 2003 Apr; 32(4):421-6. PubMed ID: 12689686
[TBL] [Abstract][Full Text] [Related]
23. New biochemical markers of bone resorption in the study of postmenopausal osteoporosis.
de la Piedra C; Traba ML; Dominguez Cabrera C; Sosa Henríquez M
Clin Chim Acta; 1997 Sep; 265(2):225-34. PubMed ID: 9385464
[TBL] [Abstract][Full Text] [Related]
24. Urinary bone resorption markers in monitoring treatment of symptomatic osteoporosis.
Parviainen MT; Jääskeläinen K; Kröger H; Arnala I; Alhava E
Clin Chim Acta; 1999 Jan; 279(1-2):145-54. PubMed ID: 10064126
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of a fully automated serum assay for C-terminal cross-linking telopeptide of type I collagen in osteoporosis.
Garnero P; Borel O; Delmas PD
Clin Chem; 2001 Apr; 47(4):694-702. PubMed ID: 11274020
[TBL] [Abstract][Full Text] [Related]
26. The carboxy-terminal pyridinoline cross-linked telopeptide of type I collagen in serum as a marker of bone resorption: the effect of nandrolone decanoate and hormone replacement therapy.
Hassager C; Jensen LT; Pødenphant J; Thomsen K; Christiansen C
Calcif Tissue Int; 1994 Jan; 54(1):30-3. PubMed ID: 8118750
[TBL] [Abstract][Full Text] [Related]
27. Application of a new serum assay for type I collagen cross-linked N-telopeptides: assessment of diurnal changes in bone turnover with and without alendronate treatment.
Gertz BJ; Clemens JD; Holland SD; Yuan W; Greenspan S
Calcif Tissue Int; 1998 Aug; 63(2):102-6. PubMed ID: 9685512
[TBL] [Abstract][Full Text] [Related]
28. Measurement of bone degradation products in serum using antibodies reactive with an isomerized form of an 8 amino acid sequence of the C-telopeptide of type I collagen.
Bonde M; Garnero P; Fledelius C; Qvist P; Delmas PD; Christiansen C
J Bone Miner Res; 1997 Jul; 12(7):1028-34. PubMed ID: 9200001
[TBL] [Abstract][Full Text] [Related]
29. Higher efficacy of urinary bone resorption marker measurements in assessing response to treatment for osteoporosis in postmenopausal women.
Abe Y; Ishikawa H; Fukao A
Tohoku J Exp Med; 2008 Jan; 214(1):51-9. PubMed ID: 18212487
[TBL] [Abstract][Full Text] [Related]
30. The predictive value of biochemical markers of bone turnover for bone mineral density in postmenopausal Japanese women.
Chaki O; Yoshikata I; Kikuchi R; Nakayama M; Uchiyama Y; Hirahara F; Gorai I
J Bone Miner Res; 2000 Aug; 15(8):1537-44. PubMed ID: 10934652
[TBL] [Abstract][Full Text] [Related]
31. Circulating levels of osteoclast activating cytokines, interleukin-11 and transforming growth factor-beta2, as valuable biomarkers for the assessment of bone turnover in postmenopausal osteoporosis.
Shaarawy M; Zaki S; Sheiba M; El-Minawi AM
Clin Lab; 2003; 49(11-12):625-36. PubMed ID: 14651333
[TBL] [Abstract][Full Text] [Related]
32. Markers of bone resorption--measurement in serum, plasma or urine?
Huber F; Traber L; Roth HJ; Heckel V; Schmidt-Gayk H
Clin Lab; 2003; 49(5-6):203-7. PubMed ID: 15285175
[TBL] [Abstract][Full Text] [Related]
33. Urinary bone resorption markers (deoxypyridinoline and C-terminal telopeptide of type I collagen) in healthy persons, postmenopausal osteoporosis and patients with type I diabetes.
Fassbender WJ; Gödde M; Brandenburg VM; Usadel KH; Stumpf UC
Adv Med Sci; 2009; 54(1):1-6. PubMed ID: 19482729
[TBL] [Abstract][Full Text] [Related]
34. A semimechanistic and mechanistic population PK-PD model for biomarker response to ibandronate, a new bisphosphonate for the treatment of osteoporosis.
Pillai G; Gieschke R; Goggin T; Jacqmin P; Schimmer RC; Steimer JL
Br J Clin Pharmacol; 2004 Dec; 58(6):618-31. PubMed ID: 15563360
[TBL] [Abstract][Full Text] [Related]
35. Bone turnover and bone collagen maturation in osteoporosis: effects of antiresorptive therapies.
Byrjalsen I; Leeming DJ; Qvist P; Christiansen C; Karsdal MA
Osteoporos Int; 2008 Mar; 19(3):339-48. PubMed ID: 17846859
[TBL] [Abstract][Full Text] [Related]
36. Assessment of urinary bone markers for monitoring treatment of osteoporosis.
Worsfold M; Powell DE; Jones TJ; Davie MW
Clin Chem; 2004 Dec; 50(12):2263-70. PubMed ID: 15472034
[TBL] [Abstract][Full Text] [Related]
37. Applications of an enzyme immunoassay for a new marker of bone resorption (CrossLaps): follow-up on hormone replacement therapy and osteoporosis risk assessment.
Bonde M; Qvist P; Fledelius C; Riis BJ; Christiansen C
J Clin Endocrinol Metab; 1995 Mar; 80(3):864-8. PubMed ID: 7883844
[TBL] [Abstract][Full Text] [Related]
38. Urinary excretion of type I collagen crosslinked N-telopeptides in healthy Japanese adults: age- and sex-related changes and reference limits.
Sone T; Miyake M; Takeda N; Fukunaga M
Bone; 1995 Oct; 17(4):335-9. PubMed ID: 8573404
[TBL] [Abstract][Full Text] [Related]
39. The measurement of urinary amino-terminal telopeptides of type I collagen to monitor bone resorption in patients with primary hyperparathyroidism.
Minisola S; Pacitti MT; Rosso R; Pellegrino C; Ombricolo E; Pisani D; Romagnoli E; Damiani C; Aliberti G; Scarda A; Mazzuoli SF
J Endocrinol Invest; 1997 Oct; 20(9):559-65. PubMed ID: 9413811
[TBL] [Abstract][Full Text] [Related]
40. Evidence that serum NTx (collagen-type I N-telopeptides) can act as an immunochemical marker of bone resorption.
Clemens JD; Herrick MV; Singer FR; Eyre DR
Clin Chem; 1997 Nov; 43(11):2058-63. PubMed ID: 9365389
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
